

February 20th, 2024

Subject: Appeal for Resubmission of SPG50's CLN2 Application to CIRM

Dear CIRM Board,

As the board is aware, we requested our application to be considered a Tier 2 application last month. However, given that this request does not align with CIRM's policy and to prevent setting precedents, the board decided to allow us to resubmit within the standards six months after the original GWG review, which will occur in June in our case.

We have carefully reviewed the feedback from the review committee and have taken necessary steps to address any concerns raised by the review panel. We are confident that the revisions made to our application will address the issues highlighted and strengthen the overall proposal.

We understand that the board intends to restrict all application except for Tier 2 resubmissions, and we are requesting the board to please allow us to re-submit during this pause.

We have drug being made and will be ready to treat these children in July/August assuming funding is approved. Based on the many people that have contacted me after learning of the CIRM pause in new applications, once the board votes to allow new submissions there will most likely be hundreds of applications potentially delaying our program a year or more.

Given the significance of our project and the potentially benefits it holds for the field of precision medicine, we kindly request the opportunity to resubmit our application during the upcoming June cycle. We are committed to adhering to the guidelines and requirements outlined by CIRM and are optimistic about the possibility of securing funding for our research.

Thank you for considering our appeal. We appreciate the opportunity to present our case for reconsideration and remain hopeful for a positive outcome.

Sincerely,



Terry Pirovolakis
CEO/Founder
Elpida Therapeutics